z-logo
open-access-imgOpen Access
The Role of the TGF-β Coreceptor Endoglin in Cancer
Author(s) -
Eduardo Pérez-Gómez,
Gaelle del Castillo,
Juan Francisco Santibáñez,
Jose Miguel Lêpez-Novoa,
Carmelo Bernabéu,
Miguel Quintanilla
Publication year - 2010
Publication title -
the scientific world journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.453
H-Index - 93
eISSN - 2356-6140
pISSN - 1537-744X
DOI - 10.1100/tsw.2010.230
Subject(s) - endoglin , cancer research , metastasis , angiogenesis , carcinogenesis , transforming growth factor , transforming growth factor beta , cancer , malignancy , receptor , medicine , biology , pathology , microbiology and biotechnology , stem cell , cd34
Endoglin (CD105) is an auxiliary membrane receptor of transforming growth factor beta (TGF-β) that interacts with type I and type II TGF-β receptors and modulates TGF-β signaling. Endoglin is overexpressed in the tumor-associated vascular endothelium, where it modulates angiogenesis. This feature makes endoglin a promising target for antiangiogenic cancer therapy. In addition, recent studies on human and experimental models of carcinogenesis point to an important tumor cell-autonomous role of endoglin by regulating proliferation, migration, invasion, and metastasis. These studies suggest that endoglin behaves as a suppressor of malignancy in experimental and human epithelial carcinogenesis, although it can also promote metastasis in other types of cancer. In this review, we evaluate the implication of endoglin in tumor development underlying studies developed in our laboratories in recent years.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom